Sentiment-Signal
19,0
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 21.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoint |
| 29.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☐ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoint |
Stammdaten
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Unternehmen & Branche
| Name | Immunovant, Inc. |
|---|---|
| Ticker | IMVT |
| CIK | 0001764013 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 5,52 Mrd. USD |
| Beta | 0,67 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | -110,635,000 | -0.61 | 1,052,392,000 | 986,135,000 | |
| 2025-09-30 | 10-Q | -126,502,000 | -0.73 | 582,959,000 | 519,705,000 | |
| 2025-06-30 | 10-Q | -120,613,000 | -0.71 | 661,440,000 | 608,540,000 | |
| 2025-03-31 | 10-K | -413,840,000 | -2.73 | 776,222,000 | 707,447,000 | |
| 2024-12-31 | 10-Q | -111,122,000 | -0.76 | 420,932,000 | 352,617,000 | |
| 2024-09-30 | 10-Q | -109,119,000 | -0.74 | 515,707,000 | 449,054,000 | |
| 2024-06-30 | 10-Q | -87,150,000 | -0.60 | 589,678,000 | 544,660,000 | |
| 2024-03-31 | 10-K | -259,336,000 | -1.88 | 666,365,000 | 617,757,000 | |
| 2023-12-31 | 10-Q | -51,418,000 | -0.36 | 711,446,000 | 679,344,000 | |
| 2023-09-30 | 10-Q | -58,662,000 | -0.45 | 292,070,000 | 251,811,000 | |
| 2023-06-30 | 10-Q | -73,937,000 | -0.57 | 351,222,000 | 299,865,000 | |
| 2023-03-31 | 10-K | -210,960,000 | -1.71 | 405,838,000 | 362,494,000 | |
| 2022-12-31 | 10-Q | -63,227,000 | -0.49 | 456,243,000 | 414,678,000 | |
| 2022-09-30 | 10-Q | -47,928,000 | -0.41 | 428,146,000 | 395,748,000 | |
| 2022-06-30 | 10-Q | -40,373,000 | -0.35 | 458,656,000 | 436,493,000 | |
| 2022-03-31 | 10-K | -156,730,000 | -1.43 | 515,564,000 | 469,825,000 | |
| 2021-12-31 | 10-Q | -41,385,000 | -0.36 | 543,182,000 | 505,148,000 | |
| 2021-09-30 | 10-Q | -37,703,000 | -0.35 | 566,732,000 | 536,397,000 | |
| 2021-06-30 | 10-Q | -30,471,000 | -0.31 | 388,027,000 | 365,532,000 | |
| 2021-03-31 | 10-K | -107,431,000 | -1.22 | 412,489,000 | 391,480,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-23 | Girao Tiago | Officer, Chief Financial Officer | Open Market Sale | -25,760 | 29.62 | -763,011.20 | -6,9% | |
| 2026-04-23 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -2,754 | 29.62 | -81,573.48 | -0,7% | |
| 2026-04-08 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -8,722 | 24.83 | -216,567.26 | -2,0% | |
| 2026-04-08 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -8,614 | 24.83 | -213,885.62 | -1,9% | |
| 2026-04-08 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1,518 | 24.83 | -37,691.94 | -0,3% | |
| 2026-04-08 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -5,165 | 24.83 | -128,246.95 | -1,2% | |
| 2026-04-02 | Venker Eric | Director, Officer, Chief Executive Officer | Open Market Sale | -12,820 | 24.04 | -308,192.80 | -2,8% | |
| 2026-04-02 | Venker Eric | Director, Officer, Chief Executive Officer | Open Market Sale | -1,409 | 24.60 | -34,661.40 | -0,3% | |
| 2026-03-18 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -2,877 | 24.97 | -71,838.69 | -0,6% | |
| 2026-02-25 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -1,437 | 26.98 | -38,770.26 | -0,4% | |
| 2026-02-25 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -942 | 28.90 | -27,223.80 | -0,2% | |
| 2026-02-25 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -859 | 28.16 | -24,189.44 | -0,2% | |
| 2026-01-21 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1,977 | 26.03 | -51,461.31 | -0,5% | |
| 2026-01-07 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -55 | 26.92 | -1,480.60 | 0,0% | |
| 2026-01-07 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1,148 | 26.51 | -30,433.48 | -0,3% | |
| 2025-12-18 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -8,529 | 26.78 | -228,406.62 | -2,1% | |
| 2025-12-18 | Van Tuyl Christopher | Officer, Chief Legal Officer | Open Market Sale | -2,284 | 27.38 | -62,535.92 | -0,6% | |
| 2025-12-12 | Roivant Sciences Ltd. | Director, 10% Owner | Open Market Purchase | 16,666,666 | 21.00 | 349,999,986.00 | +3165,9% | |
| 2025-12-01 | Hughes Douglas J. | Director | Open Market Sale | -13,091 | 23.14 | -302,925.74 | -2,7% | |
| 2025-12-01 | Hughes Douglas J. | Director | Open Market Sale | -1,909 | 23.96 | -45,739.64 | -0,4% | |
| 2025-12-01 | Fromkin Andrew J. | Director | Open Market Sale | -19,351 | 23.14 | -447,782.14 | -4,1% | |
| 2025-12-01 | Fromkin Andrew J. | Director | Open Market Sale | -2,898 | 23.95 | -69,407.10 | -0,6% | |
| 2025-11-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -2,375 | 23.97 | -56,928.75 | -0,5% | |
| 2025-11-20 | Gloria Melanie | Officer, Chief Operating Officer | Open Market Sale | -10,251 | 23.54 | -241,308.54 | -2,2% | |
| 2025-10-22 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -2,520 | 19.03 | -47,955.60 | -0,4% | |
| 2025-10-22 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -2,595 | 19.03 | -49,382.85 | -0,4% | |
| 2025-10-08 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1,585 | 16.30 | -25,835.50 | -0,2% | |
| 2025-10-08 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -1,272 | 16.30 | -20,733.60 | -0,2% | |
| 2025-07-23 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -2,805 | 18.15 | -50,910.75 | -0,5% | |
| 2025-07-23 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -2,385 | 18.15 | -43,287.75 | -0,4% | |
| 2025-07-09 | Stout Jay S | Officer, Chief Technology Officer | Open Market Sale | -1,519 | 17.24 | -26,187.56 | -0,2% | |
| 2025-07-09 | Geffner Michael | Officer, Chief Medical Officer | Open Market Sale | -1,160 | 17.24 | -19,998.40 | -0,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.